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Abstract: Hepatic complications are a common side-effect of alcoholism. Without the detoxification capabilities of the 
liver, alcohol misuse induces changes in gene and protein expression throughout the body. A global proteomics approach 
was used to identify these protein changes in the brain. We utilised human autopsy tissue from the superior frontal gyrus 
(SFG) of six cirrhotic alcoholics, six alcoholics without comorbid disease, and six non-alcoholic non-cirrhotic controls. 
Synaptic proteins were isolated and used in two-dimensional differential in-gel electrophoresis coupled with mass   
spectrometry. Many expression differences were confined to one or other alcoholic sub-group. Cirrhotic alcoholics 
showed 99 differences in protein expression levels from controls, of which half also differed from non-comorbid alcohol-
ics. This may reflect differences in disease severity between the sub-groups of alcoholics, or differences in patterns   
of harmful drinking. Alternatively, the protein profiles may result from differences between cirrhotic and non-comorbid 
alcoholics in subjects’ responses to alcohol misuse. Ten proteins were identified in at least two spots on the 2D gel;  
they were involved in basal energy metabolism, synaptic vesicle recycling, and chaperoning. These post-translationally 
modified isoforms were differentially regulated in cirrhotic alcoholics, indicating a level of epigenetic control not   
previously observed in this disorder. 
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INTRODUCTION 
  Excessive consumption of alcohol affects many parts of 
the body, including the brain and the liver [1]. Liver damage 
amongst alcoholics ranges from reversible steatosis charac-
terised by impaired metabolic and detoxifying functions, to 
irreversible, and often fatal, micronodular cirrhosis [2]. Cir-
rhosis of the liver is not an inevitable outcome for alcoholics: 
many factors influence the progression from fatty liver to 
cirrhosis, including gender, genetics, nutrition and level of 
alcohol intake [2]. In consequence, cirrhosis is not found in 
all alcoholics; however, alcoholism is the most common 
cause of cirrhosis in developed countries [3]. 
  The recent explosion in the application of proteomics to 
the study of neurodegenerative disease can be attributed to 
rapid technological advances in methodology. The ‘classical’ 
proteomics approach consists of two-dimensional electro-
phoresis (2DE) coupled to mass spectrometry (MS), and is 
still a powerful tool for comparative protein profiling. It is 
particularly useful in analyses of post-translationally modi-
fied proteins, as this ‘visual’ technique enables each protein 
and its isoforms to be observed on the 2D gel. Post-
translationally modified proteins are highly abundant in the 
human proteome [4]: in some tissues, all gene products are 
represented by an average of three to five multiple protein 
expression forms (MPEFs) [5]. Research into the regulation 
of post-translational modifications is in its infancy, but is   
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beginning to show that regulation of protein level is only a 
fraction of the changes that occur in the disease state; major 
changes to MPEF levels in disease are responsible for altered 
function. The mechanisms regulating these modifications 
(such as phosphorylation, acetylation, S-nitrosylation, glyco-
sylation, ubiquitin-like-modifier conjugation, etc), which can 
also be studied with proteomics, are essential parts of the 
processes by which disease brings about cellular changes.  
MATERIALS AND METHODS 
Case Selection 
  Subjects were categorized according to alcohol intake. 
Alcoholics were defined by National Health and Medical 
Research Council/WHO criteria as individuals who had con-
sumed an average of more than 80 g ethanol/day throughout 
most of their adult life; the alcohol consumption of controls 
was < 20 g ethanol/day. Cases with multiple drug use or 
Wernicke-Korsakoff syndrome were excluded. Controls had 
no history of brain dysfunction, and no significant brain ab-
normalities were detected by post-mortem examination. Six 
controls and six alcoholic cases were chosen and matched as 
closely as possible for age, sex and post-mortem interval. 
Subject details are shown in Table 1. 
  Samples were collected by qualified pathologists from 
the Brisbane node of the National Health and Medical Re-
search Council (NHMRC) Brain Bank and the Tissue Re-
source Centre at the University of Sydney, Australia. Full 
ethical clearance and informed written consent was obtained 
from the next of kin. 
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Protein Extraction 
  Synaptosomes were prepared as per [6]. 
2D-Differential In-gel Electrophoresis (DIGE) 
  CyDye labelling and 2-dimensional electrophoresis were 
performed as per [6]. A dye-swapping approach was utilized 
to minimize the effects of variable CyDye labelling effi-
ciency. In essence, half of each group (control, non-
comorbid alcoholics, or cirrhotic alcoholics) was labelled 
with Cy3, and the other half was labelled with Cy5. An in-
ternal standard (IS) was created by mixing 20 μg protein 
from all subjects, which was divided into 12 x 16 μg aliquots 
and labelled with Cy2. 
Comparative Analysis 
  Gels were scanned on a Typhoon 9400 scanner (GE 
Lifesciences, Princeton, NJ, USA) at three wavelengths to 
record the fluorescence of each of the three Cy Dyes in the 
gel. Images were cropped and rotated in Image Quant (Bio-
Rad, Hercules, CA, USA), then imported into the TT900 
S2S (NonLinear Dynamics, Newcastle upon Tyne, UK) im-
age alignment module for gel/spot alignment of all gels to 
each other. Aligned gels were imported into Progenesis 
PG240 (NonLinear Dynamics) then automatically analyzed 
using the SameSpots module to accurately compare the same 
protein spot in each gel. Automatic analysis included back-
ground subtraction and radiometric normalization. Differ-
ences in normalized spot volumes between gels were ana-
lyzed in Statistica (Statsoft, Tulsa, OK, USA) using analysis 
of covariance (ANCOVA) with post-mortem delay and age 
as covariants. Pairwise differences were assessed with 
Newman-Keuls post-hoc test. Only proteins with expression 
differences greater than 1.2-fold and Newman-Keuls P val-
ues  0.05 were analyzed in this study. 
Mass Spectrometry 
  Trypsin digest, matrix assisted laser desorption-ionisation 
time-of-flight (MALDI-TOF) mass spectrometry and data 
processing were performed as described in [6]. 
RESULTS AND DISCUSSION 
  The synaptic proteins were isolated from human brain 
tissue collected at autopsy that had been slowly frozen and 
stored in isotonic 0.32 M sucrose solution to minimise dam-
age to sub-cellular structures by ice crystals [7]. Both groups 
of alcoholics had lower mean ages at death (non-comorbid 
alcoholics: 50.2 ± 5.0 years; cirrhotic alcoholics: 58.7 ± 6.1 
years; mean ± SEM) than the controls (68.0 ± 5.6 years); this 
generally reflects the characteristics of such subjects col-
lected by the Queensland Brain Bank. Although these differ-
ences were not significant this partly reflects the spread of 
Table 1.  Case Demographics 
   Sex  Age (yr)  PMI (hr)  Neuropathology  Liver Pathology 
M  71  4.75  small lacunar infarct  mild microvascular steatosis 
M  75  36.5  negligible Alzheimer type changes  mild congestion 
M  67  67  old cortical infarct, L. Front cortex  acute centrilobular haemorrhage 
M 52 61.75  normal  macrovesicular  steatosis 
M 89 17 normal  nd 
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F 54  15.75  normal  nd 
M 49 16 normal  vesicular  steatosis;  early  fibrosis 
M 34 31 nd  mild  fatty  change 
M  44  22.5  mild folial atrophy, vermis  no pathology 
F 46  16.5  normal  mild  fibrosis 
M 59 15 normal  moderate  fatty  change 
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M 69 36 normal  centrilobular  steatosis 
M  58  6  old vermal white matter lesion   hepatic cirrhosis 
M 54 24 superior  vermal  atrophy  cirrhosis 
M 88 14.5  normal  multinodular  cirrhosis 
M 46 24 normal  cirrhosis 
M 50 24 cerebellar  vermal  atrophy  micronodular  cirrhosis 
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M  56  85  vascular defect in left Occ lobe  micronodular hepatic cirrhosis 
PMI, post-mortem interval; nd, not determined. 124    Current Neuropharmacology, 2011, Vol. 9, No. 1  Etheridge et al. 
values (Table 1) and the sample size. The groups were quite 
well matched on the delay between death and autopsy (post-
mortem interval; PMI) but the spread in these values was 
also quite notable (Table 1). As these factors might influence 
the amounts of proteins detected on the gels, and also con-
tribute to sample variance, age and PMI were included as 
covariants in the statistical analysis. 
  The proteomic analysis aimed to identify two sets of pro-
teins representing the effects on the brain of alcohol misuse 
combined with liver dysfunction. To do this, we obtained 
synaptosomal proteins from three groups of subjects. The 
first comparison identified the set of proteins that differed 
significantly between cirrhotic alcoholics and normal, non-
alcoholic controls. These proteins represent the end result of 
the effects of chronic alcoholism combined with the addi-
tional effects of cirrhosis. Ninety-nine proteins fell into this 
category. Alcoholics who develop cirrhosis of the liver gen-
erally have higher lifetime alcohol consumption than non-
cirrhotic alcoholics [2]; hence, the proteins that differ in con-
centration from controls in frontal cortex may do so simply 
in response to the severity of the chronic alcohol abuse. 
However, the set of proteins that are differentially expressed 
when non-cirrhotic alcoholics are compared with controls are 
quite different [6], indicating that human brain proteins are 
regulated differently in alcoholics with comorbid cirrhosis 
than in alcoholics without liver dysfunction. 
  This result was further supported when proteins that were 
differentially expressed between non-cirrhotic and cirrhotic 
alcoholics were identified. In this second comparison, 118 
proteins were differentially regulated; less than 50% of these 
were the same as those that differed from controls (Fig. (1)). 
Brain proteins in cirrhotic alcoholics appeared to have been 
regulated in a different manner from those in non-cirrhotic 
alcoholics. This differential regulation might be due to ge-
netic, nutritional, or other factors; but the data suggest that 
consumption alone is not sufficient to explain the disparity. 
  Proteins that showed significant expression differences 
between cirrhotic alcoholics and the other two groups were 
identified by their peptide-mass fingerprints (PMF) after 
trypsin digestion using matrix assisted laser desorp-
tion/ionization-time of flight (MALDI-TOF) mass spec-
trometry. The PMF of each protein was compared against a 
database containing the theoretical PMFs of all known hu-
man proteins. The identification was considered accurate 
when at least five peptides from the unknown PMF matched 
a theoretical PMF with a difference in mass of 0.0030% or 
less. These and other criteria (see Methods) reduced the 
probability of false identification. 
  Several of the proteins differentially expressed in cir-
rhotic alcoholics were identified in more than one spot on the 
2D gel (Table 2). These multiple protein expression forms 
(MPEFs) are either the result of alternate splicing, or they are 
post-translationally modified isoforms of the same tran-
scripts [8]. MPEFs represent a large proportion of the human 
proteome [4, 5, 8], and are often only visible with two-
dimensional separation techniques. We identified ten pro-
teins on the 2D gel in two or more isoforms that were differ-
entially regulated in cirrhotic alcoholics (Fig. (2); Table 2). 
Other, undetected MPEFs of these proteins may be present 
on the gel; however, our aim was to study the proteins that 
were differentially regulated by liver dysfunction in alcohol-
ics: not all proteins on the gel were subjected to MALDI-
TOF MS. 
  Most of these proteins were found in ‘strings’ of the 
same molecular weight but with varying isoelectric points 
(pI) (Fig. (2)), although one protein, L-lactate dehydrogenase 
H subunit (LDH-B; Fig. (2)), was identified in two isoforms 
of the same pI but slightly different molecular weights. No 
splice variants of LDH-B are known that could produce two 
proteins of different sizes. This indicates that these isoforms 
may be post-translationally modified in a way that does not 
alter pI. All of these proteins are known to have phosphory-
lated MPEFs (Table 3), and some are known to be methy-
lated, acetylated, S-nitrosylated or ubiquitin-like-protein 
conjugated (Table 3). The combination of these and other, 
yet to be discovered, modifications may be responsible   
for the different isoforms of these proteins observed on the 
2D gel. 
  Many of the identified proteins are involved in basal en-
ergy metabolism (Aconitase, ACO2; ATP-synthases, ATP-
syn; Glyceraldehyde-3-phosphate dehydrogenase, GAPDH; 
LDH-B; brain glycogen phosphorylase, PYG-B). In our 
study, several isoforms of ACO2, ATP-syn , ATP-syn  
and GAPDH showed lower expression in cirrhotic alcoholics 
than in controls (Fig. (2)), indicative of an alteration in   
carbohydrate metabolism in brain. This metabolic change 
 
 
 
 
 
Fig. (1). Numbers of protein expression changes between cirrhotic alcoholics and either non-cirrhotic alcoholics or controls. The pie chart 
shows the extent of protein that increases and decreases within three ranges: 1.2-1.5, 1.6-1.9, >2; the numbers in brackets indicate the num-
bers of proteins in that category. Only differences greater than 1.2 fold with a P value  0.05 (ANCOVA with Newman-Keuls post-hoc; val-
ues are corrected for post-mortem delay and age) are listed. Identifying Changes in the Synaptic Proteome of Cirrhotic Alcoholics  Current Neuropharmacology, 2011, Vol. 9, No. 1    125 
Table 2.  Summary of Proteins Identified in More than one Spot on the 2D Gel 
 MALDI-TOF  Significance  Scores
a Alcoholics  cf. Cirr.A
b Cirr.A  cf. Controls
c 
Isoform  MASCOT Score  Expect Score  Hits  % Cov  Diff.  P-values*  Diff.  P-values* 
ACO2; Aconitate hydratase. SwissProt Acc: Q99798 
i1 123 1.10E-07  15  25  1.199 0.184  -1.474 0.0135 
i2 125 6.90E-08  15  26  1.247 0.122  -1.563 0.0062 
HSP70-1; Heat shock 70 kDa protein 1. SwissProt Acc: P08107 
i1 98 2.70E-05  11  21  -1.745  0.0021  1.036 0.729 
i2 177 3.10E-13  13  36  -1.219  0.0360  1.337  0.0155 
HSP70-8; Heat shock 70 kDa protein 8. SwissProt Acc: P11142 
i1 141 1.50E-09  13  38  -1.391  0.0029  -1.061 0.440 
i2 162 9.70E-12  13  41  1.052 0.217  1.110 0.0267 
i3 100 1.50E-05  10  29  1.174  0.0368  -1.047 0.458 
ATP5A1; ATP synthase,  subunit. SwissProt Acc: P25705 
i1 71 1.60E-02  7  15  1.605  0.0488  -1.473 0.058 
i2 133 7.70E-09  12  33  3.486  0.0057  -2.962  0.0100 
i3 142 9.70E-10  14  32  -1.014 0.872  -1.228 0.0176 
i4 80 2.10E-03  7  18  1.226 0.249  -1.611 0.0160 
ATP5B; ATP synthase,  subunit. SwissProt Acc: P06576 
i1 175 6.10E-13  17  58  1.375  0.0404  -1.439  0.0478 
i2 156 3.90E-11  15  59  1.391  0.0445  -1.459  0.0529 
GAPDH; glyceraldehyde-3-phosphate dehydrogenase. SwissProt Acc: P04406 
i1 86 3.40E-04  8  25  1.856  0.0270  -1.149 0.614 
i2 162 9.70E-12  13  39  1.205  0.0442  -1.240  0.0523 
LDHB; L-lactate dehydrogenase B chain. SwissProt Acc: P07195 
i1 136 5.10E-09  14  41  -1.095 0.313  1.357 0.0188 
i2 88 2.60E-04  7  22  -1.060 0.499  1.320 0.0269 
NSF; N-ethylmaleimide-sensitive factor. SwissProt Acc: P46459 
i1 168 2.40E-12  18  25  -1.242  0.0368  1.287  0.0481 
i2 143 7.70E-10  15  22  -1.270  0.0385  1.205  0.0445 
PYGB; brain glycogen phosphorylase. SwissProt Acc: P11216 
i1 182 1.20E-13  18  27  -1.411  0.0130  1.456  0.0217 
i2 64 6.40E-02  9  13  -1.259  0.0249  1.259  0.0600 
Dynamin-1. SwissProt Acc: Q05193 
i1 85 6.40E-04  10  14  -1.806  0.0236  -1.150 0.405 
i2 80 2.20E-03  12  16  -1.527  0.0122  1.106 0.362 
i3 79 2.30E-03  13  18  -1.417  0.0043  -1.026 0.767 
i4 159 2.40E-11  16  17  -1.530  0.0005  1.322  0.0022 
i5 122 1.20E-07  12  21  -1.369  0.0084  1.152 0.100 
i6 119 2.40E-07  12  22  -1.316  0.0067  1.103 0.170 
i7 136 4.80E-09  13  22  -1.294  0.0061  1.079 0.243 
i8 149 2.40E-10  15  14  -1.348  0.0172  1.075 0.397 
Cirr.A, cirrhotic alcoholics. 
a, MALDI-TOF significance scores: MASCOT score, a measure of the statistical significance of a match generated during the MASCOT search. Protein 
scores greater than the database score (NCBInr Homo sapiens score = 64) are significant. Expect score, the number of times you would expect to get this score, or better, by chance; 
Hits, the number of experimental peptides found to match the protein in the database; % Cov, the amount that the matched peptides match the identified protein sequence. *, P values 
generated by Newman-Keuls post-hoc correction of ANCOVA values. 
b, A positive expression change indicates a protein that is higher in alcoholics than in cirrhotic alcoholics. 
c, A 
positive expression change indicates a protein that is higher in cirrhotic alcoholics than in controls. Grey, italicized numbers indicate non-significant values. 126    Current Neuropharmacology, 2011, Vol. 9, No. 1  Etheridge et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Protein expression levels in controls, non-cirrhotic alcoholics and cirrhotic alcoholics displayed in topographic and bar graph form. 
Graphs: average normalized volumes of each protein (derived from the average of 6 biological replicate samples per group), ± SEM. Topog-
raphic display: *, Values for cirrhotic alcoholics significantly (Newman Keuls p-value <0.05) different from controls. #, values for cirrhotic 
alcoholics significantly different from alcoholics. , proteins positively identified as similar to the other isoforms nearby. Other protein identi-
fications are indicated. MDH, malate dehydrogenase. PYG-B, brain variant of glycogen phosphorylase. 
 
may have led to the higher expression of PYG-B in cirrhotic 
alcoholics (Fig. (2)), since this enzyme catalyses the conver-
sion of brain glycogen to glucose. PYG-B expression may be 
increased as a compensatory response to reduced or impaired 
glycolysis. LDH-B expression was also higher in cirrhotic 
alcoholics (Fig. (2)), most likely indicating the cytotoxic 
effects of alcohol on the brain [9]. 
  Ethanol administration induces 70 kDa heat shock pro-
teins (HSP70s) expression [10, 11] as part of the protective 
response against alcohol-induced oxidative stress [12]. Our 
data suggests that only some of the MPEFs of HSP70-1 and 
HSP70-8 are increased in cirrhotic alcoholics; some MPEFs 
do not change in comparison with controls (Fig. (2); 
HSP70). Additionally, most isoforms studied showed differ-
ent regulation in non-comorbid alcoholics (Fig. (2); HSP70; 
[6]). Oxidative stress is a major cause of hepatic damage in 
alcoholic liver disease [13], and thus an increase in certain 
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ticular isoforms in cerebral protection mechanisms against 
oxidative damage. 
  N-ethylmaleimide-sensitive factor (NSF) and dynamin 1 
(DYN1) also demonstrated significant variation in the 
brain’s response to alcoholism in the presence and absence 
of cirrhosis. These proteins are both related to synaptic vesi-
cle fusion and recycling; the levels of both differed signifi-
cantly between non-comorbid and cirrhotic alcoholics,   
particularly DYN1, for which MPEFs were significantly 
lower in non-comorbid alcoholics than in controls [6],   
but not did not differ, or were slightly higher, in cirrhotic 
alcoholics (Fig. (2)). Dynamin is essential to synaptic   
signalling [14, 15], and the variation in DYN1 MPEF levels 
between cirrhotic and non-comorbid alcoholics implies that 
this process is differently affected in these groups. 
  Analysis of the MPEFs identified in this study showed 
significant epigenetic regulation of proteins in the superior 
frontal gyrus of cirrhotic alcoholics. This regulation was 
disease-state specific, with significant differences between 
MPEF regulation in non-comorbid and cirrhotic alcoholics. 
Further analysis of the types of post-translational modifica-
tions responsible for MPEF formation, and their regulation 
in different disease states, will provide insight into the 
mechanisms causing cerebral damage in comorbid and non-
comorbid alcoholics. 
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